Creyon Bio Appoints Venture Capital Titans to Board

Creyon Bio Appoints Venture Capital Titans to Board

By Daniella Parra Creyon Bio has added two prominent venture capitalists, Serge Messerlian from DCVC Bio and Shaquille Vayda from Lux Capital, to its Board of Directors, it said. The company said Messerlian has a background in hematology, oncology, and...

Agilent California Lab to Accelerate Precision Medicine

Agilent California Lab to Accelerate Precision Medicine

By Karen Roman Agilent Technologies, Inc. (NYSE: A) said it opened Biopharma CDx Services Lab in Carpinteria, California. The laboratory will contribute to drug development, therapeutics and precision medicine, as well as early clinical studies through regulatory approval, it said...

Infinite Reality, Google Cloud Partner to Improve Audience Engagement

Infinite Reality, Google Cloud Partner to Improve Audience Engagement

By Karen Roman Infinite Reality, an AI and immersive technologies company going public via Newbury Street Acquisition Corp. (Nasdaq: NBST), said it entered a five-year partnership with Google Cloud to improve audience engagement across e-commerce, sports & entertainment, education and...

Creyon Bio Secures U.S. Patent for AI-Driven Platform

Creyon Bio Secures U.S. Patent for AI-Driven Platform

By Daniella Parra Creyon Bio has received a U.S. patent for its AI-driven platform that designs safer and more effective oligonucleotide-based medicines (OBMs), it said. This company said the platform’s success includes advancing a program from concept to patient treatment...

Nanox’s Upgraded AI Cardiac Solution Receives FDA Clearance

Nanox’s Upgraded AI Cardiac Solution Receives FDA Clearance

By Karen Roman Medical imaging company Nano-X Imaging Ltd. (Nasdaq: NNOX) said it received clearance from the Food and Drug Administration for HealthCCSng V2.0, an upgraded version of its advanced AI cardiac solution HealthCCSng. HealthCCSng assesses coronary artery calcium levels...

Kohl’s Shares Rally on Bullish Full Year Profit Guidance

Kohl’s Shares Rally on Bullish Full Year Profit Guidance

By Karen Roman Kohl’s Corporation (NYSE: KSS) shares jumped 6% in early trade Wednesday as sales dropped but bullish guidance gave investors cheer. Net sales decreased 4.2% year-over-year to $3.5 billion with comparable sales down 5.1%, while inventory declined 9%,...

Input your search keywords and press Enter.